Renin-angiotensin system inhibitors plus beta-blockers
Renin-angiotensin system inhibitors plus beta-blockers has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Aug 3, 2026: “Secondary prevention of myocardial infarction in people with dementia: a multi-jurisdictional retrospective cohort study in Asia, Europe and the USA”.
1 paper studies it1 findingUpdated
“except that using RASI and a beta-blocker without a statin was associated with a lower risk of recurrent MI (HR 0.85; 95% CI, 0.75-0.96)”
- 1 lab in 1 country
- Funder: Department of Health and Human Services, State Government of Victoria
- 1 of 1 finding with company ties
- Humans1
What is Renin-angiotensin system inhibitors plus beta-blockers linked with?
1Studies link Renin-angiotensin system inhibitors plus beta-blockers with 1 measure, most often recurrent myocardial infarction (1 study).
Recurrent myocardial infarction
downin humans1HR 0.85
1 study
Recurrent myocardial infarction
downin humans1HR 0.85
Renin-angiotensin system inhibitors plus beta-blockers are linked with a lower risk of recurrent myocardial infarction in humans (without statin, compared with all three medications, in people with dementia) (HR 0.85; 95% CI 0.75-0.96).
“except that using RASI and a beta-blocker without a statin was associated with a lower risk of recurrent MI (HR 0.85; 95% CI, 0.75-0.96)”
Humanswithout statin, compared with all three medications, in people with dementia
Age and ageing